Anti-Xa based dosing of enoxaparin in hematopoietic stem cell transplant and adoptive cell therapy patients: A single center experience. Thromb Res 2022 Mar;211:6-9
Date
01/21/2022Pubmed ID
35051832DOI
10.1016/j.thromres.2022.01.012Scopus ID
2-s2.0-85123020405 (requires institutional sign-in at Scopus site)Author List
Jizzini M, Akhtar OS, Atwood K, Ji W, Pleskow J, Bat T, Balderman SAuthor
Othman S. Akhtar MBBS Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnticoagulantsCell- and Tissue-Based Therapy
Enoxaparin
Factor Xa Inhibitors
Hematopoietic Stem Cell Transplantation
Heparin, Low-Molecular-Weight
Humans
Venous Thromboembolism